A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients
Alain Bousquet-Mélou, Anne Lespine, Jean-François Sutra, Isabelle Bargues, Pierre-Louis Toutain
Frontiers in Pharmacology, doi:10.3389/fphar.2021.666348
Ivermectin (IVM) and moxidectin (MOX) are used extensively as parasiticides in veterinary medicine. Based on in vitro data, IVM has recently been proposed for the prevention and treatment of COVID-19 infection, a condition for which obesity is a major risk factor. In patients, IVM dosage is based on total body weight and there are no recommendations to adjust dosage in obese patients. The objective of this study was to establish, in a canine model, the influence of obesity on the clearance and steady-state volume of distribution of IVM, MOX, and a third analog, eprinomectin (EPR). An experimental model of obesity in dogs was based on a high calorie diet. IVM, MOX, and EPR were administered intravenously, in combination, to a single group of dogs in two circumstances, during a control period and when body weight had been increased by 50%. In obese dogs, clearance, expressed in absolute values (L/day), was not modified for MOX but was reduced for IVM and EPR, compared to the initial control state. However, when scaled by body weight (L/day/kg), plasma clearance was reduced by 55, 42, and 63%, for IVM, MOX and EPR, respectively. In contrast, the steady-state volume of distribution was markedly increased, in absolute values (L), by obesity. For IVM and MOX, this obese dog model suggests that the maintenance doses in the obese subject should be based on lean body weight rather than total weight. On the other hand, the loading dose, when required, should be based on the total body weight of the obese subject.
ETHICS STATEMENT The animal study was reviewed and approved. No specific animal experiments were carried out. The publication is based on a more advanced and focused analysis of data published in 2009 in the form of a Meeting Abstract and which was incorporated in a pharmacy thesis defended in 2011. All animal procedures were conducted in accordance with accepted standards of humane animal care required at that time under agreement number 31-242 for animal experimentation from the French Ministry of Agriculture.
AUTHOR CONTRIBUTIONS AB-M was responsible for the study design and contributed to data analysis and interpretation. AL and J-FS were responsible for analytical quantification of the investigated substances. IB conducted the animal phase and managed the data sets. P-LT contributed to data analysis and interpretation and he wrote the first draft of the manuscript. All co-authors made intellectual input into the study and critically reviewed several drafts of the manuscript.
SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.666348/ full#supplementary-material Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2021 Bousquet-Mélou, Lespine, Sutra, Bargues and Toutain. This is an open-access article distributed under..
References
Alvinerie, Sutra, Badri, Galtier, Determination of Moxidectin in Plasma by High-Performance Liquid Chromatography with Automated Solidphase Extraction and Fluorescence Detection, J. Chromatogr. B: Biomed. Sci. Appl,
doi:10.1016/0378-4347(95)00294-5Bargues, Influence De L'obesite Sur Les Parametres Pharmacocinetiques De Trois Substances Antiparasitaires Lipophiles
Bargues, Lespine, Toutain, Bousquet-Melou, Influence of Obesity on the Pharmacokinetics of Anthelmintic Macrocyclic Lactones in Dogs, J. Vet. Pharmacol. Ther
Baudou, Lespine, Durrieu, André, Gandia et al., Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations, N. Engl. J. Med,
doi:10.1056/NEJMc1917344Bernigaud, Fang, Fischer, Lespine, Aho et al., Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model, Plos Negl. Trop. Dis,
doi:10.1371/journal.pntd.0005030Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: A Report in Antiviral Research, Widespread Interest, an FDA Warning, Two Letters to the Editor and the Authors' Responses, Antiviral Res,
doi:10.1016/j.antiviral.2020.104805Camprubí, Almuedo-Riera, Martí-Soler, Soriano, Hurtado et al., Lack of Efficacy of Standard Doses of Ivermectin in Severe COVID-19 Patients, PLoS One,
doi:10.1371/journal.pone.0242184Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and COVID-19: Keeping Rigor in Times of Urgency, Am. J. Trop. Med. Hyg,
doi:10.4269/ajtmh.20-0271Chandler, Serious Neurological Adverse Events after Ivermectin-Do They Occur beyond the Indication of Onchocerciasis?, Am. J. Trop. Med. Hyg,
doi:10.4269/ajtmh.17-0042Chawla, Rizzo, Zalocusky, Keebler, Chia et al., Descriptive Epidemiology of 16,780 Hospitalized COVID-19 Patients in the United States,
doi:10.1101/2020.07.17.20156265Cupp, Sauerbrey, Richards, Elimination of Human Onchocerciasis: History of Progress and Current Feasibility Using Ivermectin (Mectizan ® ) Monotherapy, Acta Tropica,
doi:10.1016/j.actatropica.2010.08.009Di Filippo, De Lorenzo, D'amico, Sofia, Roveri et al., COVID-19 Is Associated with Clinically Significant Weight Loss and Risk of Malnutrition, Independent of Hospitalisation: A post-hoc Analysis of a Prospective Cohort Study, Clin. Nutr,
doi:10.1016/j.clnu.2020.10.043Dubois, Bertrand, Mentré, Mathematical Expressions of the Pharmacokinetic and Pharmacodynamic Models Implemented in the PFIM Software
Duthaler, Suenderhauf, Karlsson, Hussner, Meyer Zu Schwabedissen et al., Population Pharmacokinetics of Oral Ivermectin in Venous Plasma and Dried Blood Spots in Healthy Volunteers, Br. J. Clin. Pharmacol,
doi:10.1111/bcp.13840Fawcett, Ivermectin Use in Scabies, Am. Fam. Physician
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, J. Clin. Pharmacol,
doi:10.1177/009127002401382731Gwee, Duffull, Zhu, Tong, Cranswick et al., Population Pharmacokinetics of Ivermectin for the Treatment of Scabies in Indigenous Australian Children, Plos Negl. Trop. Dis,
doi:10.1371/journal.pntd.0008886Han, Duffull, Kirkpatrick, Green, Dosing in Obesity: A Simple Solution to a Big Problem, Clin. Pharmacol. Ther,
doi:10.1038/sj.clpt.6100381He, Qian, Wong, Bai, He et al., N-in-1 Dosing Pharmacokinetics in Drug Discovery: Experience, Theoretical and Practical Considerations, J. Pharm. Sci,
doi:10.1002/jps.21196Heidary, Gharebaghi, Ivermectin: a Systematic Review from Antiviral Effects to COVID-19 Complementary Regimen, J. Antibiot,
doi:10.1038/s41429-020-0336-zHill, Abdulamir, Ahmed, Asghar, Babalola et al., Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection,
doi:10.21203/rs.3.rs-148845/v1Hoffmann, Mösbauer, Hofmann-Winkler, Kaul, Kleine-Weber et al., Chloroquine Does Not Inhibit Infection of Human Lung Cells with SARS-CoV-2, Nature,
doi:10.1038/s41586-020-2575-3Hutmacher, Kowalski, Covariate Selection in Pharmacometric Analyses: a Review of Methods: Covariate Selection in Pharmacometric Analysis, Br. J. Clin. Pharmacol,
doi:10.1111/bcp.12451Ivermectin, A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool, Am. J. Trop. Med. Hyg,
doi:10.4269/ajtmh.19-0620Jan, Cheng, Juang, Ma, Wu et al., Identification of Existing Pharmaceuticals and Herbal Medicines as Inhibitors of SARS-CoV-2 Infection, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.2021579118Kern, Schöning, Chaccour, Hammann, Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing, Front. Pharmacol,
doi:10.3389/fphar.2021.625678Król, Speakman, Isotope Dilution Spaces of Mice Injected Simultaneously with Deuterium, Tritium and Oxygen-18, J. Exp. Biol,
doi:10.1242/jeb.202.20.2839Lallemand, Lespine, Alvinerie, Bousquet-Melou, Toutain, Estimation of Absolute Oral Bioavailability of Moxidectin in Dogs Using a Semi-simultaneous Method: Influence of Lipid Co-administration
Lo, Fink, Williams, Blodinger, Pharmacokinetic Studies of Ivermectin: Effects of Formulation, Vet. Res. Commun,
doi:10.1007/BF02215150López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2021.3071Mawby, Bartges, D'avignon, Laflamme, Moyers et al., Comparison of Various Methods for Estimating Body Fat in Dogs, J. Am. Anim. Hosp. Assoc,
doi:10.5326/0400109Meeuwsen, Horgan, The Relationship between BMI and Percent Body Fat, Measured by Bioelectrical Impedance, in a Large Adult Sample Is Curvilinear and Influenced by Age and Sex, Clin. Nutr,
doi:10.1016/j.clnu.2009.12.011Mellon, Hermet, Toutain, Dulioust, Lespine, Scabies in an Obese Patient: How Should the Ivermectin Dosing Be Adapted?, Med. Mal Infect,
doi:10.1016/j.medmal.2018.09.007Miller, Bauer, Hartz, Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy, Pharmacol. Rev,
doi:10.1124/pr.107.07109Momekov, Momekova, Ivermectin as a Potential COVID-19 Treatment from the Pharmacokinetic point of View: Antiviral Levels Are Not Likely Attainable with Known Dosing Regimens, Biotechnol. Biotechnological Equipment,
doi:10.1080/13102818.2020.1775118Muñoz, Ballester, Antonijoan, Gich, Rodríguez et al., Safety and Pharmacokinetic Profile of Fixed-Dose Ivermectin with an Innovative 18mg Tablet in Healthy Adult Volunteers, Plos Negl. Trop. Dis,
doi:10.1371/journal.pntd.0006020Ménez, Sutra, Prichard, Lespine, Relative Neurotoxicity of Ivermectin and Moxidectin in Mdr1ab (−/−) Mice and Effects on Mammalian GABA(A) Channel Activity, Plos Negl. Trop. Dis,
doi:10.1371/journal.pntd.0001883Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of High-Dose Ivermectin: a Systematic Review and Meta-Analysis, J. Antimicrob. Chemother,
doi:10.1093/jac/dkz524Popkin, Du, Green, Beck, Algaith et al., Individuals with Obesity and COVID-19: A Global Perspective on the Epidemiology and Biological Relationships, Obes. Rev. obr,
doi:10.1111/obr.13128Prichard, Ménez, Lespine, Moxidectin and the Avermectins: Consanguinity but Not Identity, Int. J. Parasitol. Drugs Drug Resist,
doi:10.1016/j.ijpddr.2012.04.001Savic, Karlsson, Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, AAPS J,
doi:10.1208/s12248-009-9133-0Schinkel, Smit, Van Tellingen, Beijnen, Wagenaar et al., Disruption of the Mouse Mdr1a P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to Increased Sensitivity to Drugs, Cell,
doi:10.1016/0092-8674(94)90212-7Schulz, Coulibaly, Schindler, Wimmersberger, Keiser, Pharmacokinetics of Ascending Doses of Ivermectin in Trichuris Trichiura-Infected Children Aged 2-12 Years, J. Antimicrob. Chemother,
doi:10.1093/jac/dkz083Solomon, FDA Letter to Stakeholders: Do Not Use Ivermectin Intended for Animals as Treatment for COVID-19 in Humans
Sutra, Chartier, Galtier, Alvinerie, Determination of Eprinomectin in Plasma by High-Performance Liquid Chromatography with Automated Solid Phase Extraction and Fluorescence Detection, Analyst,
doi:10.1039/a802093kVerwaerde, Sénard, Galinier, Rougé, Massabuau et al., Changes in Short-Term Variability of Blood Pressure and Heart Rate during the Development of Obesity-Associated Hypertension in High-Fat Fed Dogs, J. Hypertens,
doi:10.1097/00004872-199917080-00013Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors Associated with COVID-19-Related Death Using OpenSAFELY, Nature,
doi:10.1038/s41586-020-2521-4Xia, Xiao, Liu, Pimprale, Fox et al., Comparison of Species Differences of P-Glycoproteins in Beagle Dog, Rhesus Monkey, and Human Using ATPase Activity Assays, Mol. Pharmaceutics,
doi:10.1021/mp050034j
